United Therapeutics Corporation (UTH.F)
- Previous Close
219.90 - Open
219.10 - Bid 222.40 x 30000
- Ask 222.70 x 30000
- Day's Range
219.10 - 219.10 - 52 Week Range
189.80 - 235.40 - Volume
30 - Avg. Volume
4 - Market Cap (intraday)
10.417B - Beta (5Y Monthly) 0.55
- PE Ratio (TTM)
11.80 - EPS (TTM)
18.56 - Earnings Date May 1, 2024 - May 6, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
231.89
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
www.unither.comRecent News: UTH.F
Performance Overview: UTH.F
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: UTH.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: UTH.F
Valuation Measures
Market Cap
10.46B
Enterprise Value
8.31B
Trailing P/E
11.84
Forward P/E
10.26
PEG Ratio (5yr expected)
1.30
Price/Sales (ttm)
5.01
Price/Book (mrq)
1.84
Enterprise Value/Revenue
3.57
Enterprise Value/EBITDA
5.99
Financial Highlights
Profitability and Income Statement
Profit Margin
42.31%
Return on Assets (ttm)
11.22%
Return on Equity (ttm)
18.27%
Revenue (ttm)
2.33B
Net Income Avi to Common (ttm)
984.8M
Diluted EPS (ttm)
18.56
Balance Sheet and Cash Flow
Total Cash (mrq)
2.99B
Total Debt/Equity (mrq)
12.24%
Levered Free Cash Flow (ttm)
607.29M